Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy

Robust biological signaling networks evolved, through gene duplications, from simple, relatively fragile cascades. Architectural features such as layered configuration, branching and modularity, as well as functional characteristics (e.g., feedback control circuits), enable fail‐safe performance in the face of internal and external perturbations. These universal features are exemplified here using the receptor tyrosine kinase (RTK) family. The RTK module is richly mutated and overexpressed in human malignancies, and pharmaceutical interception of its signaling effectively retards growth of specific tumors. Therapy‐induced interception of RTK‐signaling pathways and the common evolvement of drug resistance are respectively considered here as manifestations of fragility and plasticity of robust networks. The systems perspective we present views pathologies as hijackers of biological robustness and offers ways for identifying fragile hubs, as well as strategies to overcome drug resistance.

[1]  M. Freeman Feedback control of intercellular signalling in development , 2000, Nature.

[2]  L. Lau,et al.  Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[4]  H. Kitano Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.

[5]  Ivan Dikic,et al.  Negative receptor signalling. , 2003, Current opinion in cell biology.

[6]  Doyle,et al.  Highly optimized tolerance: robustness and design in complex systems , 2000, Physical review letters.

[7]  R. Stein,et al.  Evolutionary Analysis of the ErbB Receptor and Ligand Families , 2000, Journal of Molecular Evolution.

[8]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[9]  Michael Tsang,et al.  Promotion and Attenuation of FGF Signaling Through the Ras-MAPK Pathway , 2004, Science's STKE.

[10]  Wendy S. Beane,et al.  The sea urchin kinome: a first look. , 2006, Developmental biology.

[11]  R. Nahta,et al.  HER2 therapy: Molecular mechanisms of trastuzumab resistance , 2006, Breast Cancer Research.

[12]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[13]  Y. Yarden,et al.  Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases , 2004, Oncogene.

[14]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[15]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[16]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[17]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[18]  A. Smith,et al.  The complex of polyoma virus middle‐T antigen and pp60c‐src. , 1984, The EMBO journal.

[19]  Ralf J. Sommer,et al.  The evolution of signalling pathways in animal development , 2003, Nature Reviews Genetics.

[20]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[21]  Wen-Hsiung Li,et al.  Origins, lineage-specific expansions, and multiple losses of tyrosine kinases in eukaryotes. , 2004, Molecular biology and evolution.

[22]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[23]  Andrey Rzhetsky,et al.  Birth of scale-free molecular networks and the number of distinct DNA and protein domains per genome , 2001, Bioinform..

[24]  I. Verma,et al.  Regulation of proto-oncogene fos: a paradigm for early response genes. , 1988, Cold Spring Harbor symposia on quantitative biology.

[25]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[26]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[27]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[28]  Gavin MacBeath,et al.  A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.

[29]  L. Alberghina,et al.  Molecular evolution of the neurotrophin family members and their Trk receptors. , 2007, Gene.

[30]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[31]  Carine Maenhaut,et al.  Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[33]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Miyata,et al.  Divergence pattern of animal gene families and relationship with the Cambrian explosion , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[35]  Muffy Calder,et al.  When kinases meet mathematics: the systems biology of MAPK signalling , 2005, FEBS letters.

[36]  J. Doyle,et al.  Bow Ties, Metabolism and Disease , 2022 .

[37]  P. Blackshear,et al.  Feedback Inhibition of Macrophage Tumor Necrosis Factor-α Production by Tristetraprolin , 1998 .

[38]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[39]  A. Sharrocks,et al.  Id helix–loop–helix proteins inhibit nucleoprotein complex formation by the TCF ETS‐domain transcription factors , 1999, The EMBO journal.

[40]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Solé,et al.  Evolving protein interaction networks through gene duplication. , 2003, Journal of theoretical biology.

[42]  Shuang Huang,et al.  Involvement of MicroRNA in AU-Rich Element-Mediated mRNA Instability , 2005, Cell.

[43]  G. Barton,et al.  Emerging roles of pseudokinases. , 2006, Trends in cell biology.

[44]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Levine,et al.  A genomewide survey of developmentally relevant genes in Ciona intestinalis , 2003, Development Genes and Evolution.

[46]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[47]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[48]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[49]  Eytan Domany,et al.  A module of negative feedback regulators defines growth factor signaling , 2007, Nature Genetics.

[50]  B. Kholodenko Cell-signalling dynamics in time and space , 2006, Nature Reviews Molecular Cell Biology.

[51]  R. Milo,et al.  Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T. Hunter,et al.  Signaling—2000 and Beyond , 2000, Cell.

[53]  Napoleone Ferrara,et al.  VEGF as a Therapeutic Target in Cancer , 2005, Oncology.

[54]  N. Satoh,et al.  A genomewide survey of developmentally relevant genes in Ciona intestinalis , 2003, Development Genes and Evolution.

[55]  C. Tacchetti,et al.  TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. , 2005, Oncogene.

[56]  James E. Ferrell,et al.  A positive-feedback-based bistable ‘memory module’ that governs a cell fate decision , 2007, Nature.

[57]  J. Ferrell,et al.  A positive-feedback-based bistable ‘memory module’ that governs a cell fate decision , 2003, Nature.

[58]  S. Hubbard,et al.  Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.

[59]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[60]  R. Götz,et al.  BuCy RAFs drive cells into MEK addiction. , 2006, Cancer cell.

[61]  M. Borrello,et al.  The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck , 1997, Oncogene.

[62]  Karen E. Pilcher,et al.  The Dictyostelium Kinome—Analysis of the Protein Kinases from a Simple Model Organism , 2006, PLoS genetics.

[63]  C. Sawyers,et al.  Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies , 2006, TheScientificWorldJournal.

[64]  F. Bruggeman,et al.  Cancer: a Systems Biology disease. , 2006, Bio Systems.

[65]  A. Ullrich,et al.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.

[66]  M. Freeman,et al.  Control of EGF Receptor Signalling: Lessons from Fruitflies , 2004, Cancer and Metastasis Reviews.

[67]  M. Lynch,et al.  The evolutionary fate and consequences of duplicate genes. , 2000, Science.

[68]  Hiroaki Kitano,et al.  Biological robustness , 2008, Nature Reviews Genetics.

[69]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[70]  U. Alon Biological Networks: The Tinkerer as an Engineer , 2003, Science.

[71]  Carlos L Arteaga,et al.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.

[72]  Susan Lindquist,et al.  Under cover: causes, effects and implications of Hsp90‐mediated genetic capacitance , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[73]  J. Baselga,et al.  Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.

[74]  D. Tautz Evolution of transcriptional regulation. , 2000, Current opinion in genetics & development.

[75]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[76]  P. Blackshear,et al.  Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. , 1998, Science.

[77]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[78]  Paul W. Sternberg,et al.  The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily , 1990, Nature.

[79]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[80]  P. Bastiaens,et al.  Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate , 2007, Nature Cell Biology.

[81]  D. Birnbaum,et al.  Phylogenetic Analysis of Ciona intestinalis Gene Superfamilies Supports the Hypothesis of Successive Gene Expansions , 2004, Journal of Molecular Evolution.

[82]  D. Morrison,et al.  Protein Kinases and Phosphatases in the Drosophila Genome , 2000, The Journal of cell biology.

[83]  I. Weinstein Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[84]  A. Ullrich,et al.  Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion , 2004, Oncogene.

[85]  D. A. Baxter,et al.  Mathematical Modeling of Gene Networks , 2000, Neuron.

[86]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[87]  Stuart K. Kim,et al.  Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans. , 1999, Trends in genetics : TIG.

[88]  Rüdiger Klein,et al.  Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation , 2006, Nature Medicine.

[89]  Annie Z. Tremp Malaria: Plasmodium develops in lymph nodes , 2006, Nature Reviews Microbiology.

[90]  C. Vieira,et al.  Is genome size influenced by colonization of new environments in dipteran species? , 2005, Molecular ecology.

[91]  Albert,et al.  Emergence of scaling in random networks , 1999, Science.

[92]  J. Isola,et al.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. , 2005, Cancer research.

[93]  J. Stelling,et al.  Robustness of Cellular Functions , 2004, Cell.

[94]  Yosef Yarden,et al.  Cancer therapeutic antibodies come of age: Targeting minimal residual disease , 2007, Molecular oncology.

[95]  Y. Yarden,et al.  Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network , 1998, The EMBO journal.

[96]  D. Lauffenburger,et al.  Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules*S , 2005, Molecular & Cellular Proteomics.

[97]  Somasekar Seshagiri,et al.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling , 2004, Nature.